Terumo Corporation (TRUMY) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
P/E 20.14 means the share price is 20.14 times one year of earnings per share; the S&P 500 usually sits near 20-25. Market cap $21.6B is the value of all shares combined. Beta 0.25: the stock has moved about 75% less than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerTerumo Corporation (TRUMY) trades at $14.62. Terumo Corporation is a global medical device company specializing in the manufacture and sale of a wide range of medical products and equipment. Market cap: $21.6B, Sector: Healthcare.
Price as of Sep 11, 2026 · Last analyzed: Mar 15, 2026Analyst Coverage for TRUMY: TRUMY does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates TRUMY against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
These figures come from statements filed 12 months ago — the most recent this company has published.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
TRUMY: 2/2 scored disciplines lean bullish. Dominant signal: Izzy Englander bullish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Terumo Corporation (TRUMY) Healthcare & Pipeline Overview
Terumo Corporation, a Japanese medical device manufacturer, develops, produces, and distributes a diverse portfolio of medical products and equipment across three segments, including cardiac and vascular, medical care solutions, and blood and cell technologies, serving a global healthcare market with a focus on innovation and quality.
What Is the Investment Thesis for TRUMY?
With a market capitalization of $21.6B and a P/E ratio of 20.14, Terumo demonstrates financial stability. The company's 11.7% profit margin and 53.3% gross margin indicate efficient operations. Growth catalysts include expanding its presence in emerging markets and continuous innovation in its core product segments. Potential risks include regulatory changes in the medical device industry and increased competition from established players and new entrants. The company's beta of 0.25 suggests lower volatility compared to the overall market.
Based on FMP financials and quantitative analysis
TRUMY Key Highlights
Market capitalization of $21.6B, reflecting its significant presence in the medical device industry.
- P/E ratio of 20.14, indicating investor confidence in its earnings potential.
- Profit margin of 11.7%, showcasing efficient operations and profitability.
- Gross margin of 53.3%, highlighting the company's ability to maintain strong pricing power.
- Dividend yield of 1.35%, providing a steady income stream for investors.
Who Are TRUMY's Competitors?
TRUMY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| CLPBF Coloplast A/S | $68.33 | 0.00% | $14.2B | — |
| OCPNF Olympus Corporation | $13.46 | 0.00% | $14.8B | — |
| OTSKF Otsuka Holdings Co., Ltd. | $76.10 | 0.00% | $40.0B | — |
| WST West Pharmaceutical Services, Inc. | $345.48 | +0.36% | $24.3B | 915-pillar |
| MDLN Medline Inc. Class A Common Stock | $32.53 | +0.43% | $27.5B | 695-pillar |
| RMD ResMed Inc. | $218.27 | -0.60% | $31.7B | 935-pillar |
| ALC Alcon Inc. | $66.55 | -2.75% | $32.5B | 765-pillar |
| BAX Baxter International Inc. | $24.18 | -0.86% | $12.5B | 535-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are TRUMY's Key Strengths?
Diversified product portfolio
- Global presence and distribution network
- Strong brand reputation
- Consistent profitability
What Are TRUMY's Weaknesses?
Exposure to currency fluctuations
- Dependence on regulatory approvals
- Limited presence in certain emerging markets
- Potential for product recalls
What Could Drive TRUMY Stock Higher?
TRUMY catalyst: Continued innovation in cardiac and vascular devices, leading to new product launches and market share gains.
- Expansion in emerging markets, driving revenue growth and increasing global presence.
- Potential strategic acquisitions to expand product portfolio and geographic reach.
- Growth in contract manufacturing services for pharmaceutical companies, providing a stable revenue stream.
What Are the Key Risks for TRUMY?
Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
- Increased competition from established players and new entrants in the medical device industry.
- Regulatory changes in the medical device industry, impacting product approvals and market access.
- Exposure to currency fluctuations, affecting financial results and profitability.
- Product liability claims and recalls, potentially damaging brand reputation and financial performance.
What Are the Growth Opportunities for TRUMY?
- Expansion in Emerging Markets: Terumo has the opportunity to expand its presence in emerging markets, such as China and India, where healthcare spending is rapidly increasing. These markets offer significant growth potential for Terumo's products, particularly in the cardiac and vascular and medical care solutions segments. The rising prevalence of chronic diseases and increasing access to healthcare in these regions are expected to drive demand for Terumo's medical devices and equipment. Timeline: Ongoing.
- Innovation in Cardiac and Vascular Devices: Terumo can continue to invest in research and development to develop innovative cardiac and vascular devices, such as drug-eluting stents and advanced imaging catheters. These products can address unmet clinical needs and improve patient outcomes, driving revenue growth and market share gains. The global market for cardiac and vascular devices is expected to grow at a steady pace, driven by the increasing prevalence of cardiovascular diseases. Timeline: Ongoing.
- Growth in Blood and Cell Technologies: Terumo can capitalize on the growing demand for blood and cell technologies, such as blood bags, component collection systems, and cell expansion systems. These products are essential for blood banks, hospitals, and research institutions. The increasing demand for blood transfusions and cell therapies is expected to drive growth in this segment. Timeline: Ongoing.
- Strategic Acquisitions: Terumo can pursue strategic acquisitions to expand its product portfolio, geographic reach, and technological capabilities. Acquisitions can provide access to new markets, technologies, and customer segments, accelerating growth and enhancing competitiveness. The medical device industry is characterized by consolidation, and Terumo can leverage acquisitions to strengthen its position in the market. Timeline: Ongoing.
- Contract Manufacturing for Pharmaceutical Companies: Terumo can expand its contract manufacturing services for pharmaceutical companies, providing prefilled syringes, devices for drug kits, and other products. This business offers a stable revenue stream and leverages Terumo's manufacturing expertise and infrastructure. The increasing demand for prefilled syringes and drug delivery devices is expected to drive growth in this segment. Timeline: Ongoing.
What Are TRUMY's Competitive Advantages?
- Strong brand reputation for quality and reliability.
- Diversified product portfolio across multiple medical specialties.
- Global presence with established distribution networks.
- Continuous innovation and investment in research and development.
What Does TRUMY Do?
Terumo Corporation, founded in 1921 as Sekisen Ken-onki Corporation, initially focused on manufacturing clinical thermometers. Over the decades, Terumo expanded its product line and global presence, becoming a leading manufacturer of medical devices and equipment. In October 1974, the company officially changed its name to Terumo Corporation. Today, Terumo operates through three primary segments: Cardiac and Vascular Company, which offers products such as angiographic guidewires, catheters, and stents; Medical Care Solutions Company, providing syringes, infusion pumps, and I.V. solutions; and Blood and Cell Technologies Company, which focuses on blood bags, collection systems, and cell expansion systems. Terumo's products are used in a wide range of medical settings, from hospitals and clinics to home healthcare. With its headquarters in Tokyo, Japan, Terumo has a global reach, serving customers in numerous countries and regions. The company is committed to innovation and quality, continuously developing new and improved medical technologies to meet the evolving needs of healthcare professionals and patients worldwide.
What Products and Services Does TRUMY Offer?
- Manufactures and sells angiographic guidewires and catheters.
- Produces vascular closure devices and PTCA balloon catheters.
- Develops and distributes coronary and peripheral stents.
- Offers intravascular ultrasound systems and imaging catheters.
- Provides oxygenators and cardio-pulmonary bypass systems.
- Manufactures syringes, infusion pumps, and I.V. solutions.
- Offers blood glucose monitoring systems and blood pressure monitors.
- Develops blood bags and component collection systems.
How Does TRUMY Make Money?
- Develops and manufactures a wide range of medical devices and equipment.
- Sells products through direct sales, distributors, and partnerships.
- Generates revenue from three main segments: Cardiac and Vascular, Medical Care Solutions, and Blood and Cell Technologies.
- Invests in research and development to innovate new products and improve existing ones.
What Industry Does TRUMY Operate In?
Terumo Corporation operates in the global medical device industry, which is characterized by continuous innovation, increasing regulatory scrutiny, and growing demand for advanced healthcare solutions. The industry is driven by factors such as an aging population, rising prevalence of chronic diseases, and technological advancements. Terumo competes with other major players in the medical device market, including CLPBF, CLPBY, KONEF, OCPNF, and OTSKF. The company's diversified product portfolio and global presence provide a competitive edge in this dynamic and competitive landscape.
Who Are TRUMY's Key Customers?
- Hospitals and clinics
- Blood banks and transfusion centers
- Research institutions
- Pharmaceutical companies
- Home healthcare providers
Research confidence
Enough evidence to be useful, with gaps worth knowing about.
- ● Scoring coverage unknown
- ● Price is current
- ● Latest filing 73 days ago
- ● No analyst coverage
- ● Reported in JPY, converted to USD
MoonshotScore History
Recorded daily since 2026-08-23 · 19 snapshots
| 2026-08-23 | 51 |
| 2026-08-26 | 51 |
| 2026-08-29 | 51 |
| 2026-09-01 | 51 |
| 2026-09-04 | 51 |
| 2026-09-07 | 51 |
| 2026-09-10 | 51 |
What changed?
The score has stayed at 51.
Over the same 18 days the stock moved -11.3%.
Terumo Corporation Financial Trajectory
Terumo Corporation (TRUMY) reported $2.03B in revenue for Q1 FY2027, reflecting 2.0% growth compared to the prior quarter. The company recorded net income of $458.3M, with diluted EPS of $0.31. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this large-cap Healthcare company. Across the four most recent quarters, TRUMY averaged $0.18 in diluted EPS.
Company Profile
Terumo Corporation operates in the Medical - Instruments & Supplies industry within the Healthcare sector. It is headquartered in Tokyo, JP. The company is led by CEO Hikaru Samejima. TRUMY has traded publicly since 2010.
How Terumo Corporation Is Valued
Terumo Corporation carries a market capitalization of $21.6B, placing it in the large-cap category.
Key Financial Metrics
Return on equity for Terumo Corporation stands at 10.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 6.9%, showing how much profit it generates from its asset base. TRUMY trades at a trailing price-to-earnings ratio of 20.14, roughly in line with the Healthcare sector average of ~21.50x. Its free cash flow yield is 5.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.19 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 5.0%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Terumo Corporation's Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 4.48 places it in the safe zone, indicating low near-term bankruptcy risk.
Earnings Track Record
Terumo Corporation has missed Wall Street's EPS estimate in 5 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 3.1% above estimates on average.
TRUMY Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2026
Bull Case vs Bear Case
Bull Case
- Diversified product portfolio
- Global presence and distribution network
- Strong brand reputation
- Consistent profitability
Bear Case
- Exposure to currency fluctuations
- Dependence on regulatory approvals
- Limited presence in certain emerging markets
- Potential for product recalls
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 FY2027 | $2.03B | $458M | $0.31 |
| Q4 FY2026 | $1.99B | $175M | $0.12 |
| Q3 FY2026 | $1.96B | $216M | $0.15 |
| Q2 FY2026 | $1.82B | $232M | $0.16 |
Q1 FY2027 · filed 30 Jun 2026 · Financial Modeling Prep
Based on FMP financials and quantitative analysis · Converted to USD from JPY at today's rate
TRUMY Latest News
-
Terumo Corp. (OTCMKTS:TRUMY) Short Interest Down 46.0% in July
defenseworld.net · Aug 18, 2026
-
Terumo Corporation (TRUMY) Q1 2027 Earnings Call Prepared Remarks Transcript
seekingalpha.com · Aug 12, 2026
-
Terumo Corp (TRUMF) (Q1 2027) Earnings Call Highlights: Record Revenue and Profit Surge on ...
Yahoo! Finance: TRUMY News · Aug 11, 2026
-
Terumo (OTCMKTS:TRUMY) Shares Gap Up on Strong Earnings
defenseworld.net · Aug 11, 2026
TRUMY Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for TRUMY.
Price Targets
Wall Street price target analysis for TRUMY.
TRUMY MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for TRUMY; grades run from A+ (80-100) to F (below 30).
Latest News
Terumo Corp. (OTCMKTS:TRUMY) Short Interest Down 46.0% in July
Terumo Corporation (TRUMY) Q1 2027 Earnings Call Prepared Remarks Transcript
Terumo Corp (TRUMF) (Q1 2027) Earnings Call Highlights: Record Revenue and Profit Surge on ...
Terumo (OTCMKTS:TRUMY) Shares Gap Up on Strong Earnings
Leadership: Hikaru Samejima
Managing Director
Hikaru Samejima serves as a Managing Director at Terumo Corporation, overseeing a global workforce of over 30,000 employees. As a key leader within Terumo, Samejima plays a crucial role in shaping the company's strategic direction and driving its growth initiatives in the competitive medical device industry.
Track Record: Specific achievements and milestones under Hikaru Samejima's leadership are not detailed in the provided data. However, as a Managing Director, he is responsible for guiding Terumo's overall performance, including its financial results, product innovation, and market expansion efforts. His leadership is essential for maintaining Terumo's position as a leading global medical device manufacturer.
Terumo Corporation ADR Information Unsponsored
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company trading on U.S. stock exchanges. TRUMY, as an ADR, allows U.S. investors to invest in Terumo Corporation without the complexities of cross-border transactions. Each TRUMY ADR represents a specific number of Terumo Corporation's shares traded on its home market.
- Home Market Ticker: Tokyo Stock Exchange, Japan
- ADR Level: 1
- ADR Ratio: 1:1
- Home Market Ticker: TRUM
TRUMY OTC Market Information
The OTC Other tier represents the lowest tier of the over-the-counter (OTC) market. Companies trading on this tier typically have limited or no financial disclosure requirements, making it difficult for investors to assess their financial health and performance. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies are not subject to stringent listing standards or regulatory oversight, which increases the risk for investors.
- OTC Tier: OTC Other
- Limited financial disclosure
- Low trading volume and liquidity
- Potential for price manipulation
- Lack of regulatory oversight
- Higher risk of fraud or scams
- Verify the company's registration and legal status.
- Research the company's management team and their track record.
- Attempt to obtain audited financial statements, if available.
- Assess the company's business model and competitive landscape.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Be wary of unsolicited investment offers or promotions.
- Established history as Terumo Corporation
- Global presence and operations
- Presence in the medical device industry
- ADR status, indicating some level of regulatory compliance
Terumo Corporation Healthcare Stock: Key Questions Answered
Is TRUMY a good stock?
Stock Expert AI does not rate TRUMY buy, sell or hold. Terumo Corporation has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What does Terumo Corporation do?
Terumo Corporation is a global medical device company that develops, manufactures, and distributes a wide range of medical products and equipment. Its three main segments are Cardiac and Vascular, which offers products like catheters and stents; Medical Care Solutions, providing syringes and infusion pumps; and Blood and Cell Technologies, focusing on blood bags and cell expansion systems.
What are the key factors to evaluate for TRUMY?
Evaluate TRUMY on fundamentals, analyst consensus, and risk factors. P/E: 20.14x vs the S&P 500's ~20-25x. Growth catalysts include expanding its presence in emerging markets and continuous innovation in its core product segments. Not financial advice.
How frequently does TRUMY data refresh on this page?
TRUMY's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 calculations are scheduled daily at 10:15 UTC; the score's own date shows its last successful run.
What has driven TRUMY's recent stock price performance?
Terumo Corporation (TRUMY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diversified product portfolio. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider TRUMY overvalued or undervalued right now?
Terumo Corporation (TRUMY) trades at 20.14x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of TRUMY?
Yes, most major brokerages offer fractional shares of Terumo Corporation (TRUMY) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track TRUMY's earnings and financial reports?
Terumo Corporation (TRUMY) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for TRUMY earnings announcements.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.